Cadrenal Therapeutics, Inc. Common Stock

NasdaqCM CVKD

Cadrenal Therapeutics, Inc. Common Stock Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

Cadrenal Therapeutics, Inc. Common Stock Net Cash Used Provided By Financing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqCM: CVKD

Cadrenal Therapeutics, Inc. Common Stock

CEO	Mr. Quang X. Pham
IPO Date	Jan. 20, 2023
Location	United States
Headquarters	822 A1A North
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key trends

Past 5 years